Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-1 and IFNγ inhibition during COVID-19 inflammation (Anakinra and Ruxolitinib)
2020-001963-10Phase 3Completed
- Sponsor
- Centre Hospitalier Intercommunal de Toulon-La Seyne-sur-Mer
- Start
- Apr 2020
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing Anakinra monotherapy with Anakinra + Ruxolitinib combination (2 arms). Primary endpoint: Biological response criteria. Started Apr 2020; status: completed.
02
Drugs
anakinraruxolitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001963-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001963-10.